Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor, in Combination with PEGylated Interferon and Ribavirin
Crossref DOI link: https://doi.org/10.1007/7355_2018_57
Published Online: 2019-06-13
Published Print: 2019
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kwong, Ann D.
Perni, Robert B.
Graham, Camilla S.
Text and Data Mining valid from 2019-01-01
Version of Record valid from 2019-01-01
Chapter History
First Online: 13 June 2019